| 000 | 01689 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250518005230.0 | ||
| 264 | 0 | _c20190225 | |
| 008 | 201902s 0 0 eng d | ||
| 022 | _a1879-0712 | ||
| 024 | 7 |
_a10.1016/j.ejphar.2018.10.036 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSafaroghli-Azar, Ava | |
| 245 | 0 | 0 |
_aAnticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance. _h[electronic resource] |
| 260 |
_bEuropean journal of pharmacology _cJan 2019 |
||
| 300 |
_a89-98 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAminopyridines _xpharmacology |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aCaspase 3 _xmetabolism |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xdrug effects |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aG2 Phase Cell Cycle Checkpoints _xdrug effects |
| 650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aM Phase Cell Cycle Checkpoints _xdrug effects |
| 650 | 0 | 4 |
_aMorpholines _xpharmacology |
| 650 | 0 | 4 |
_aMultiple Myeloma _xpathology |
| 650 | 0 | 4 | _aPhosphoinositide-3 Kinase Inhibitors |
| 650 | 0 | 4 |
_aTumor Protein p73 _xmetabolism |
| 700 | 1 | _aBashash, Davood | |
| 700 | 1 | _aKazemi, Alireza | |
| 700 | 1 | _aPourbagheri-Sigaroodi, Atieh | |
| 700 | 1 | _aMomeny, Majid | |
| 773 | 0 |
_tEuropean journal of pharmacology _gvol. 842 _gp. 89-98 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ejphar.2018.10.036 _zAvailable from publisher's website |
| 999 |
_c29017612 _d29017612 |
||